51
|
Andreou C, Oseledchyk A, Nicolson F, Berisha N, Pal S, Kircher MF. Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting. J Vis Exp 2019. [PMID: 30958459 DOI: 10.3791/58389] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Ovarian cancer represents the deadliest gynecologic malignancy. Most patients present at an advanced stage (FIGO stage III or IV), when local metastatic spread has already occurred. However, ovarian cancer has a unique pattern of metastatic spread, in that tumor implants are initially contained within the peritoneal cavity. This feature could enable, in principle, the complete resection of tumor implants with curative intent. Many of these metastatic lesions are microscopic, making them hard to identify and treat. Neutralizing such micrometastases is believed to be a major goal towards eliminating tumor recurrence and achieving long-term survival. Raman imaging with surface enhanced resonance Raman scattering nanoprobes can be used to delineate microscopic tumors with high sensitivity, due to their bright and bioorthogonal spectral signatures. Here, we describe the synthesis of two 'flavors' of such nanoprobes: an antibody-functionalized one that targets the folate receptor - overexpressed in many ovarian cancers - and a non-targeted control nanoprobe, with distinct spectra. The nanoprobes are co-administered intraperitoneally to mouse models of metastatic human ovarian adenocarcinoma. All animal studies were approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center. The peritoneal cavity of the animals is surgically exposed, washed, and scanned with a Raman microphotospectrometer. Subsequently, the Raman signatures of the two nanoprobes are decoupled using a Classical Least Squares fitting algorithm, and their respective scores divided to provide a ratiometric signal of folate-targeted over untargeted probes. In this way, microscopic metastases are visualized with high specificity. The main benefit of this approach is that the local application into the peritoneal cavity - which can be done conveniently during the surgical procedure - can tag tumors without subjecting the patient to systemic nanoparticle exposure. False positive signals stemming from non-specific binding of the nanoprobes onto visceral surfaces can be eliminated by following a ratiometric approach where targeted and non-targeted nanoprobes with distinct Raman signatures are applied as a mixture. The procedure is currently still limited by the lack of a commercial wide-field Raman imaging camera system, which once available will allow for the application of this technique in the operating theater.
Collapse
Affiliation(s)
| | | | - Fay Nicolson
- Department of Radiology, Memorial Sloan Kettering Cancer Center
| | - Naxhije Berisha
- Department of Radiology, Memorial Sloan Kettering Cancer Center; Department of Chemistry, The Graduate Center of the City University of New York
| | - Suchetan Pal
- Department of Radiology, Memorial Sloan Kettering Cancer Center
| | - Moritz F Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center; Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center; Gerstner Sloan Kettering Graduate School of Biomedical Sciences; Department of Radiology, Weill Cornell Medical College of Cornell University; Dana-Farber Cancer Institute and Harvard Medical Center;
| |
Collapse
|
52
|
Zhang L, Su H, Wang H, Li Q, Li X, Zhou C, Xu J, Chai Y, Liang X, Xiong L, Zhang C. Tumor Chemo-Radiotherapy with Rod-Shaped and Spherical Gold Nano Probes: Shape and Active Targeting Both Matter. Am J Cancer Res 2019; 9:1893-1908. [PMID: 31037146 PMCID: PMC6485290 DOI: 10.7150/thno.30523] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Accepted: 01/20/2019] [Indexed: 12/13/2022] Open
Abstract
The morphologies of gold nanoparticles (NPs) affect their tumor accumulation through enhanced permeability and retention effect. However, detailed information and mechanisms of NPs' characteristics affecting tumor accumulation are limited. The aim of this study is to evaluate the effects of shape and active targeting ligands of theranostic NPs on tumor accumulation and therapeutic efficacy, and to elucidate the underlying mechanism. Methods:αvβ3 integrin-targeted, cisplatin-loaded and radioisotope iodine-125 labeled spherical and rod-shaped gold nano theranostic probes (RGD-125IPt-AuNPs and RGD-125IPt-AuNRs) with similar sizes were fabricated and characterized. The in vivo distribution and chemo-radio therapeutic efficacy against tumors of these newly developed probes were subsequently evaluated. Moreover, a physiologically based pharmacokinetic (PBPK) model was developed to characterize the in vivo kinetics of these probes at the sub-organ level, and to reveal the mechanism of NPs' shape and active targeting ligands effects on tumor accumulation. Result: Cisplatin and iodine-125 were loaded sequentially onto the NPs through a thin polydopamine coating layer on the NPs. Both RGD-125IPt-AuNPs and RGD-125IPt-AuNRs exhibited high specificity for αvβ3 in vitro, with the rod-shaped probe being more efficient. The PBPK model revealed that rod-shaped gold NPs diffused more rapidly in tumor interstitial than the spherical ones. Tumor accumulations of non-targeted and rod-shaped RAD-125IPt-AuNRs was higher in short term (1 h post injection), but not pronounced and similar to that of non-targeted spherical RAD-125IPt-AuNPs in 24 h after intravenous injection, revealing that the NPs' shape did not have a significant impact on tumor accumulations through enhanced permeability and retention (EPR) effect in long-term. While for actively targeted NPs, in addition to a higher distribution coefficient, RGD-125IPt-AuNRs also had a much higher tumor maximum uptake rate constant than RGD-125IPt-AuNPs, indicating both the shape and active targeting ligands affected the tumor uptake of rod-shaped NPs. As a result, RGD-125IPt-AuNRs had a more effective inhibition of tumor growth than RGD-125IPt-AuNPs by chemo-radiationtherapy. Conclusion: Our study suggests that both the shape and active targeting ligands of gold NPs play important roles on tumor accumulation and chemo-radio therapeutic effect.
Collapse
|
53
|
A Promising Biocompatible Platform: Lipid-Based and Bio-Inspired Smart Drug Delivery Systems for Cancer Therapy. Int J Mol Sci 2018; 19:ijms19123859. [PMID: 30518027 PMCID: PMC6321581 DOI: 10.3390/ijms19123859] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Revised: 11/29/2018] [Accepted: 12/02/2018] [Indexed: 02/06/2023] Open
Abstract
Designing new drug delivery systems (DDSs) for safer cancer therapy during pre-clinical and clinical applications still constitutes a considerable challenge, despite advances made in related fields. Lipid-based drug delivery systems (LBDDSs) have emerged as biocompatible candidates that overcome many biological obstacles. In particular, a combination of the merits of lipid carriers and functional polymers has maximized drug delivery efficiency. Functionalization of LBDDSs enables the accumulation of anti-cancer drugs at target destinations, which means they are more effective at controlled drug release in tumor microenvironments (TMEs). This review highlights the various types of ligands used to achieve tumor-specific delivery and discusses the strategies used to achieve the effective release of drugs in TMEs and not into healthy tissues. Moreover, innovative recent designs of LBDDSs are also described. These smart systems offer great potential for more advanced cancer therapies that address the challenges posed in this research area.
Collapse
|
54
|
Greish K, Pittalà V, Taurin S, Taha S, Bahman F, Mathur A, Jasim A, Mohammed F, El-Deeb IM, Fredericks S, Rashid-Doubell F. Curcumin⁻Copper Complex Nanoparticles for the Management of Triple-Negative Breast Cancer. NANOMATERIALS 2018; 8:nano8110884. [PMID: 30388728 PMCID: PMC6267006 DOI: 10.3390/nano8110884] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Revised: 10/24/2018] [Accepted: 10/25/2018] [Indexed: 12/30/2022]
Abstract
Breast cancer is the most common cancer diagnosed among females worldwide. Although breast cancer survival has largely improved in the past 30 years, it remains highly heterogeneous in its response to treatment. Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor-2 (Her2). While TNBC may initially be responsive to chemotherapy, recurrence and subsequent high mortality rates are frequently reported. Studies have shown curcumin and its derivatives to be effective against TNBC cell lines in vitro. To improve its anti-cancer effects, we have synthesized Fe3+⁻curcumin (Fe⁻Cur₃) and Cu2+⁻curcumin (CD) complexes and investigated them experimentally. Further, CD was encapsulated into a poly(styrene)-co-maleic acid (SMA) micelle to enhance its stability. We assessed the cytotoxicity of these formulations both in vitro and in vivo. SMA⁻CD demonstrated dose-dependent cytotoxicity and abolished TNBC tumor growth in vivo. The encapsulation of the curcumin⁻copper complex improved its anti-cancer activity without overt adverse effects in a murine model of TNBC. These results provide evidence and insights into the value of nanoformulations in enhancing drug-delivery and increasing the potential therapeutic efficacy of curcumin derivatives.
Collapse
Affiliation(s)
- Khaled Greish
- Department of Molecular Medicine, College of Medicine and Medical Sciences, and Nanomedicine Research Unite, Princess Al-Jawhara Centre for Molecular Medicine and Inherited Disorder, Arabian Gulf University, Manama 328, Bahrain.
- Department of Oncology, Suez Canal University, Ismailia 007, Egypt.
| | - Valeria Pittalà
- Department of Drug Sciences, University of Catania, Catania I-95125, Italy.
| | - Sebastien Taurin
- Department of Molecular Medicine, College of Medicine and Medical Sciences, and Nanomedicine Research Unite, Princess Al-Jawhara Centre for Molecular Medicine and Inherited Disorder, Arabian Gulf University, Manama 328, Bahrain.
| | - Safa Taha
- Department of Molecular Medicine, College of Medicine and Medical Sciences, and Nanomedicine Research Unite, Princess Al-Jawhara Centre for Molecular Medicine and Inherited Disorder, Arabian Gulf University, Manama 328, Bahrain.
| | - Fatemah Bahman
- Department of Molecular Medicine, College of Medicine and Medical Sciences, and Nanomedicine Research Unite, Princess Al-Jawhara Centre for Molecular Medicine and Inherited Disorder, Arabian Gulf University, Manama 328, Bahrain.
| | - Aanchal Mathur
- Department of Molecular Medicine, College of Medicine and Medical Sciences, and Nanomedicine Research Unite, Princess Al-Jawhara Centre for Molecular Medicine and Inherited Disorder, Arabian Gulf University, Manama 328, Bahrain.
| | - Anfal Jasim
- Department of Molecular Medicine, College of Medicine and Medical Sciences, and Nanomedicine Research Unite, Princess Al-Jawhara Centre for Molecular Medicine and Inherited Disorder, Arabian Gulf University, Manama 328, Bahrain.
| | - Fatima Mohammed
- Department of Basic Medical Sciences, Royal College of Surgeons in Ireland (RCSI), Medical University of Bahrain, Busaiteen 221, Bahrain.
| | - Ibrahim M El-Deeb
- Department of Basic Medical Sciences, Royal College of Surgeons in Ireland (RCSI), Medical University of Bahrain, Busaiteen 221, Bahrain.
| | - Salim Fredericks
- Department of Basic Medical Sciences, Royal College of Surgeons in Ireland (RCSI), Medical University of Bahrain, Busaiteen 221, Bahrain.
| | - Fiza Rashid-Doubell
- Department of Basic Medical Sciences, Royal College of Surgeons in Ireland (RCSI), Medical University of Bahrain, Busaiteen 221, Bahrain.
| |
Collapse
|
55
|
Luo Z, Tian H, Liu L, Chen Z, Liang R, Chen Z, Wu Z, Ma A, Zheng M, Cai L. Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose. Theranostics 2018; 8:3584-3596. [PMID: 30026868 PMCID: PMC6037038 DOI: 10.7150/thno.25409] [Citation(s) in RCA: 73] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Accepted: 05/01/2018] [Indexed: 12/21/2022] Open
Abstract
Hypoxia is a characteristic feature of solid tumors and an important causation of resistance to chemotherapy and photodynamic therapy (PDT). It is challenging to develop efficient functional nanomaterials for tumor oxygenation and therapeutic applications. Methods: Through disulfide reconfiguration to hybridize hemoglobin and albumin, tumor-targeted hybrid protein oxygen carriers (HPOCs) were fabricated, serving as nanomedicines for precise tumor oxygenation and simultaneous enhancement of hypoxia-dampened chemotherapy and photodynamic therapy. Based on encapsulation of doxorubicin (DOX) and chlorin e6 (Ce6) into HPOCs to form ODC-HPOCs, the mechanism and therapeutic efficacy of oxygen-enhanced chemo-PDT was investigated in vitro and in vivo. Results: The precise oxygen preservation and release of the HPOC guaranteed sufficient tumor oxygenation, which is able to break hypoxia-induced chemoresistance by downregulating the expressions of hypoxia-inducible factor-1α (HIF-1α), multidrug resistance 1 (MDR1) and P-glycoprotein (P-gp), resulting in minimized cellular efflux of chemodrug. Moreover, the oxygen supply is fully exploited for upgrading the generation of reactive oxygen species (ROS) during the photodynamic process. As a result, only a single-dose treatment of the HPOCs-based chemo-PDT exhibited superior tumor suppression. The combination therapy was guided by in vivo fluorescence/photoacoustic imaging with nanoparticle tracking and oxygen monitoring. Conclusion: This well-defined HPOC as a versatile nanosystem is expected to pave a new way for breaking multiple hypoxia-induced therapeutic resistances to achieve highly effective treatment of solid tumors.
Collapse
|
56
|
Neuschmelting V, Harmsen S, Beziere N, Lockau H, Hsu HT, Huang R, Razansky D, Ntziachristos V, Kircher MF. Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Optoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2018; 14:e1800740. [PMID: 29726109 PMCID: PMC6541212 DOI: 10.1002/smll.201800740] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 03/22/2018] [Indexed: 06/08/2023]
Abstract
Difficulty in visualizing glioma margins intraoperatively remains a major issue in the achievement of gross total tumor resection and, thus, better clinical outcome of glioblastoma (GBM) patients. Here, the potential of a new combined optical + optoacoustic imaging method for intraoperative brain tumor delineation is investigated. A strategy using a newly developed gold nanostar synthesis method, Raman reporter chemistry, and silication method to produce dual-modality contrast agents for combined surface-enhanced resonance Raman scattering (SERRS) and multispectral optoacoustic tomography (MSOT) imaging is devised. Following intravenous injection of the SERRS-MSOT-nanostars in brain tumor bearing mice, sequential MSOT imaging is performed in vivo and followed by Raman imaging. MSOT is able to accurately depict GBMs three-dimensionally with high specificity. The MSOT signal is found to correlate well with the SERRS images. Because SERRS enables uniquely sensitive high-resolution surface detection, it could represent an ideal complementary imaging modality to MSOT, which enables real-time, deep tissue imaging in 3D. This dual-modality SERRS-MSOT-nanostar contrast agent reported here is shown to enable high precision depiction of the extent of infiltrating GBMs by Raman- and MSOT imaging in a clinically relevant murine GBM model and could pave new ways for improved image-guided resection of brain tumors.
Collapse
Affiliation(s)
- Volker Neuschmelting
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
- Department of Neurosurgery, University Hospital Cologne, Cologne, Germany
- Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center, Munich, Germany
- These authors contributed equally to this work
| | - Stefan Harmsen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
- These authors contributed equally to this work
| | - Nicolas Beziere
- Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center, Munich, Germany
| | - Hannah Lockau
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Hsiao-Ting Hsu
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Ruimin Huang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
- Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Daniel Razansky
- Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center, Munich, Germany
| | - Vasilis Ntziachristos
- Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center, Munich, Germany
| | - Moritz F. Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
- Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, USA
- Molecular Pharmacology Program, Sloan Kettering Institute, New York, USA
- Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, USA
- Department of Radiology, Weill Cornell Medical College
| |
Collapse
|
57
|
Neuschmelting V, Harmsen S, Beziere N, Lockau H, Hsu HT, Huang R, Razansky D, Ntziachristos V, Kircher MF. Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Optoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2018; 14:e1800740. [PMID: 29726109 DOI: 10.1002/smll.v14.23] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 03/22/2018] [Indexed: 05/23/2023]
Abstract
Difficulty in visualizing glioma margins intraoperatively remains a major issue in the achievement of gross total tumor resection and, thus, better clinical outcome of glioblastoma (GBM) patients. Here, the potential of a new combined optical + optoacoustic imaging method for intraoperative brain tumor delineation is investigated. A strategy using a newly developed gold nanostar synthesis method, Raman reporter chemistry, and silication method to produce dual-modality contrast agents for combined surface-enhanced resonance Raman scattering (SERRS) and multispectral optoacoustic tomography (MSOT) imaging is devised. Following intravenous injection of the SERRS-MSOT-nanostars in brain tumor bearing mice, sequential MSOT imaging is performed in vivo and followed by Raman imaging. MSOT is able to accurately depict GBMs three-dimensionally with high specificity. The MSOT signal is found to correlate well with the SERRS images. Because SERRS enables uniquely sensitive high-resolution surface detection, it could represent an ideal complementary imaging modality to MSOT, which enables real-time, deep tissue imaging in 3D. This dual-modality SERRS-MSOT-nanostar contrast agent reported here is shown to enable high precision depiction of the extent of infiltrating GBMs by Raman- and MSOT imaging in a clinically relevant murine GBM model and could pave new ways for improved image-guided resection of brain tumors.
Collapse
Affiliation(s)
- Volker Neuschmelting
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Department of Neurosurgery, University Hospital Cologne, Cologne, 50937, Germany
- Institute for Biological and Medical Imaging, Technical University of Neuherberg and Helmholtz Center, Neuherberg, 85764, Germany
| | - Stefan Harmsen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Nicolas Beziere
- Institute for Biological and Medical Imaging, Technical University of Neuherberg and Helmholtz Center, Neuherberg, 85764, Germany
| | - Hannah Lockau
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Hsiao-Ting Hsu
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Ruimin Huang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Daniel Razansky
- Institute for Biological and Medical Imaging, Technical University of Neuherberg and Helmholtz Center, Neuherberg, 85764, Germany
| | - Vasilis Ntziachristos
- Institute for Biological and Medical Imaging, Technical University of Neuherberg and Helmholtz Center, Neuherberg, 85764, Germany
| | - Moritz F Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY, 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY, 10065, USA
| |
Collapse
|
58
|
Yu Y, Nishikawa M, Liu M, Tei T, Kaul SC, Wadhawa R, Zhang M, Takahashi J, Miyako E. Self-assembled nanodiamond supraparticles for anticancer chemotherapy. NANOSCALE 2018; 10:8969-8978. [PMID: 29664104 DOI: 10.1039/c8nr00641e] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
A nanodiamond (ND) is a promising material for drug delivery applications owing to its relatively low cost, amenability to large-scale synthesis, unique structure, and low toxicity. However, synthesizing drug-loaded ND conjugates with uniform and tunable sizes, high loading capacity, efficacy in drug delivery, and versatility in terms of surface functionalization has been challenging. Here, we show that perfluorooctanoic acid-functionalized NDs spontaneously transform into well-dispersed and biocompatible supraparticle (SP) nanoclusters. We demonstrate that the synthesized ND-based SPs (ND-SPs) exhibit high penetration through the cell membrane and are therefore superior as drug carriers for conventional nanomedicines such as polyethylene glycol and phospholipid-based nanocapsules and simple drug-loaded ND conjugates. We confirm the efficacy of ND-SPs in the eradication of cancer cells in vitro and in vivo. Our results demonstrate that the synthesized ND-SPs are useful for targeted drug delivery in a variety of biological applications.
Collapse
Affiliation(s)
- Yue Yu
- Nanomaterials Research Institute (NMRI), National Institute of Advanced Industrial Science and Technology (AIST), Central 5, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|